RTW Biotech Opportunities Ltd (RTW.L), on Wednesday, noted that Galera Therapeutics, Inc. (GRTX) has entered into a definitive agreement to merge with private portfolio company Obsidian Therapeutics Inc. in a reverse merger transaction.
The all-stock merger will be conducted alongside a $350 million private placement financing, in which RTW Biotech Opportunities is participating.
The combined company is expected to begin trading on the Nasdaq under the ticker "OBX" in the third quarter of 2026.
Obsidian, a clinical-stage biopharmaceutical company focused on cell therapies for solid tumors, is advancing its lead candidate OBX-115 in Phase 2 trials for advanced melanoma and Phase 1 trials for non-small cell lung cancer.
As of March 31, 2026, Obsidian represented approximately 0.3% of RTW Biotech Opportunities' net asset value.
On Tuesday, RTW Biotech Opportunities closed trading 3.38% higher at $2.1400 on the London Stock Exchange.
On Tuesday, Galera Therapeutics closed trading 88.10% higher at $0.0790 on the OTC.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.